|
Research
Front Name
|
Percentage of corporate affiliations
|
Leading
corporation
|
|
EARLY DRUG DISCOVERY USING HIGH-RESOLUTION LIQUID
CHROMATOGRAPHY/QUADRUPOLE TIME-OF-FLIGHT MASS
SPECTROMETRY
|
35
|
Waters Corp
|
|
FRAGMENT-BASED DRUG DISCOVERY; FRAGMENT-BASED LEAD
DISCOVERY USING X-RAY CRYSTALLOGRAPHY; FRAGMENT-BASED
DRUG DESIGN; PROTEIN KINASE INHIBITOR PHARMACOPHORE
|
33
|
Astex Technology Ltd
|
|
VIRTUAL SCREENING; PROTEIN-LIGAND DOCKING;
SIMILARITY-BASED VIRTUAL SCREENING USING 2D
FINGERPRINTS; VIRTUAL SCREENING USING MULTIPLE
BIOACTIVE REFERENCE STRUCTURES
|
32
|
Schrodinger LLC
|
|
TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND
RECEPTOR ACTIVATING AGENTS; FULLY HUMAN TRAIL-RECEPTOR
1 MONOCLONAL ANTIBODY
|
31
|
Genentech Inc
|
|
SMALL-MOLECULE MDM2 ANTAGONISTS; ABERRANT P53
SIGNALING; GENOMIC ANALYSIS IDENTIFIES P53 STATUS;
B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
|
30
|
Hoffmann-La Roche Inc
|
|
DELTA-LIKE 4 NOTCH LIGAND REGULATES TUMOR ANGIOGENESIS;
BLOCKING NEUROPILIN-2 FUNCTION INHIBITS TUMOR CELL
METASTASIS; VEGF GUIDES ANGIOGENIC SPROUTING UTILIZING
ENDOTHELIAL TIP CELL FILOPODIA
|
29
|
Genentech Inc
|
|
SUBOPTIMALLY CONTROLLED TYPE 2 DIABETES; MONOTHERAPY
SIGNIFICANTLY IMPROVES GLYCEMIC CONTROL; EXENATIDE
TREATMENT
|
27
|
Amylin Pharmaceuticals Inc
|
|
NOVEL TRANSIENT RECEPTOR POTENTIAL TYPE V1 RECEPTOR
ANTAGONIST; NOVEL TRANSIENT RECEPTOR POTENTIAL
VANILLOID TYPE 1 MODULATOR
|
25.56
|
Merck & Co
|
|
TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED; TYPE
2 DIABETES FAILING THIAZOLIDINEDIONE MONOTHERAPY;
DIPEPTIDYL PEPTIDASE-4 INHIBITOR VILDAGLIPTIN IMPROVES
BETA-CELL FUNCTION
|
25
|
Merck & Co
|
|
HIGHLY EFFICIENT ENDOGENOUS HUMAN GENE CORRECTION USING
DESIGNED ZINC-FINGER NUCLEASES; TARGETED MUTAGENESIS
USING ZINC-FINGER NUCLEASES
|
24
|
Sangamo BioSciences Inc
|
|
PLANNED PERCUTANEOUS CORONARY INTERVENTION; ACUTE
CORONARY SYNDROMES TREATED; NON-ST-SEGMENT ELEVATION
ACUTE CORONARY SYNDROME; STABLE CORONARY ARTERY DISEASE
|
24
|
Eli Lilly & Co
|
|
FULLY HUMAN ANTI-TYPE 1 INSULIN-LIKE GROWTH FACTOR
RECEPTOR MONOCLONAL ANTIBODY CP-751; INSULIN-LIKE
GROWTH FACTOR I RECEPTOR BLOCKS LIGAND-DEPENDENT
SIGNALING
|
24
|
Novartis AG
|
